Theravance Bioph Financials
This page shows Theravance Bioph (TBPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Theravance Biopharma’s recent cash inflection reflects a lumpy monetization model more than a fully profitable operating engine.
FY2025 looked transformed on the cash-flow line because operating cash flow swung from-$11.5M to$238.5M in one year. Yet operating income was still slightly negative at-$3.6M , and minimal capital spending let that inflow pass almost straight into free cash flow, so FY2025 was defined by cash arrival rather than a fully proven recurring earnings base.
The underlying operating reset started well before that cash surge: R&D spending fell from
The balance sheet is now far less constrained than the earlier debt-heavy period: total liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Theravance Bioph's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Theravance Bioph scores 1.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($880.0M) relative to total liabilities ($188.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Theravance Bioph passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Theravance Bioph generates $2.25 in operating cash flow ($238.5M OCF vs $105.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Theravance Bioph earns $-1.5 in operating income for every $1 of interest expense (-$3.6M vs $2.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Theravance Bioph generated $107.5M in revenue in fiscal year 2025. This represents an increase of 66.9% from the prior year.
Theravance Bioph's EBITDA was -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 95.4% from the prior year.
Theravance Bioph reported $105.9M in net income in fiscal year 2025. This represents an increase of 287.7% from the prior year.
Theravance Bioph earned $2.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 279.1% from the prior year.
Cash & Balance Sheet
Theravance Bioph generated $238.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2109.8% from the prior year.
Theravance Bioph held $167.8M in cash against $0 in long-term debt as of fiscal year 2025.
Theravance Bioph had 51M shares outstanding in fiscal year 2025. This represents an increase of 3.2% from the prior year.
Margins & Returns
Theravance Bioph's operating margin was -3.4% in fiscal year 2025, reflecting core business profitability. This is up 69.6 percentage points from the prior year.
Theravance Bioph's net profit margin was 98.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 186.2 percentage points from the prior year.
Theravance Bioph's ROE was 35.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 67.8 percentage points from the prior year.
Capital Allocation
Theravance Bioph invested $37.4M in research and development in fiscal year 2025. This represents a decrease of 0.6% from the prior year.
Theravance Bioph invested $42K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 87.3% from the prior year.
TBPH Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.7M-61.4% | $45.9M+129.6% | $20.0M-23.7% | $26.2M+70.2% | $15.4M-17.9% | $18.8M+11.2% | $16.9M+18.3% | $14.3M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.8M | N/A | $8.1M-22.7% | $10.5M-8.4% | $11.5M | N/A | $9.3M-6.9% | $10.0M |
| SG&A Expenses | $17.7M | N/A | $18.3M-0.5% | $18.4M+0.3% | $18.4M | N/A | $16.9M-1.1% | $17.1M |
| Operating Income | -$9.5M-147.4% | $20.0M+410.0% | -$6.5M-136.9% | -$2.7M+81.1% | -$14.4M-56.9% | -$9.2M+15.1% | -$10.8M+31.0% | -$15.7M |
| Interest Expense | N/A | N/A | $573K-13.6% | $663K+3.1% | $643K | N/A | $630K-2.2% | $644K |
| Income Tax | -$1.5M | N/A | -$6.5M-135.4% | $18.4M+3386.4% | -$559K | N/A | $2.6M+102.3% | $1.3M |
| Net Income | -$4.9M-108.1% | $61.0M+1588.1% | $3.6M-93.4% | $54.8M+503.8% | -$13.6M+12.5% | -$15.5M-22.3% | -$12.7M+23.2% | -$16.5M |
| EPS (Diluted) | $-0.10-108.7% | $1.15+1542.9% | $0.07-93.5% | $1.08+500.0% | $-0.27+12.9% | $-0.31-19.2% | $-0.26+23.5% | $-0.34 |
TBPH Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $472.3M-2.7% | $485.6M+16.9% | $415.5M-2.5% | $426.0M+24.0% | $343.6M-3.0% | $354.2M-0.5% | $356.1M-1.6% | $362.0M |
| Current Assets | $417.6M-0.2% | $418.5M+18.0% | $354.7M-3.2% | $366.3M+143.8% | $150.3M-6.7% | $161.1M+38.3% | $116.5M-2.4% | $119.3M |
| Cash & Equivalents | $288.1M+71.7% | $167.8M-4.0% | $174.8M-38.0% | $281.9M+154.9% | $110.6M+192.7% | $37.8M+61.7% | $23.4M-49.6% | $46.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $181.7M-3.8% | $188.8M+3.3% | $182.8M-9.1% | $201.2M+13.3% | $177.6M-0.6% | $178.6M+4.8% | $170.5M+1.3% | $168.3M |
| Current Liabilities | $31.8M-17.0% | $38.3M+2.4% | $37.4M-31.5% | $54.6M+73.4% | $31.5M-1.8% | $32.1M+36.9% | $23.4M+2.1% | $22.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $290.6M-2.1% | $296.7M+27.5% | $232.7M+3.5% | $224.8M+35.5% | $166.0M-5.4% | $175.5M-5.4% | $185.7M-4.1% | $193.7M |
| Retained Earnings | -$864.6M-0.6% | -$859.6M+6.6% | -$920.7M+0.4% | -$924.3M+5.6% | -$979.1M-1.4% | -$965.5M-1.6% | -$950.0M-1.4% | -$937.3M |
TBPH Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $73.3M+1308.4% | -$6.1M+6.8% | -$6.5M-103.1% | $208.1M+383.5% | $43.0M+4871.5% | -$902K+82.6% | -$5.2M-17.7% | -$4.4M |
| Capital Expenditures | N/A | $8K | $0 | N/A | N/A | $190K+1166.7% | $15K-58.3% | $36K |
| Free Cash Flow | N/A | -$6.1M+6.7% | -$6.5M | N/A | N/A | -$1.1M+79.0% | -$5.2M-17.1% | -$4.5M |
| Investing Cash Flow | $52.6M+8844.4% | $588K+100.6% | -$100.2M-176.5% | -$36.3M-218.4% | $30.6M+95.3% | $15.7M+190.2% | -$17.4M-474.0% | -$3.0M |
| Financing Cash Flow | -$5.6M-274.0% | -$1.5M-272.8% | -$400K+20.5% | -$503K+41.1% | -$854K-134.0% | -$365K+1.9% | -$372K-745.5% | -$44K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
TBPH Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -53.6%-97.2pp | 43.6%+75.9pp | -32.3%-21.9pp | -10.4%+83.4pp | -93.8%-44.7pp | -49.1%+15.2pp | -64.3%+45.9pp | -110.2% |
| Net Margin | -27.9%-160.8pp | 133.0%+114.9pp | 18.1%-191.3pp | 209.3%+297.6pp | -88.2%-5.4pp | -82.8%-7.5pp | -75.3%+40.7pp | -115.9% |
| Return on Equity | -1.7%-22.3pp | 20.6%+19.0pp | 1.6%-22.8pp | 24.4%+32.6pp | -8.2%+0.7pp | -8.8%-2.0pp | -6.8%+1.7pp | -8.5% |
| Return on Assets | -1.0%-13.6pp | 12.6%+11.7pp | 0.9%-12.0pp | 12.9%+16.8pp | -4.0%+0.4pp | -4.4%-0.8pp | -3.6%+1.0pp | -4.6% |
| Current Ratio | 13.14+2.2 | 10.93+1.4 | 9.48+2.8 | 6.70+1.9 | 4.77-0.3 | 5.02+0.0 | 4.97-0.2 | 5.20 |
| Debt-to-Equity | 0.63-0.0 | 0.64-0.1 | 0.79-0.1 | 0.89-0.2 | 1.07+0.1 | 1.02+0.1 | 0.92+0.0 | 0.87 |
| FCF Margin | N/A | -13.2%+19.3pp | -32.6% | N/A | N/A | -5.8%+25.1pp | -30.9%+0.3pp | -31.2% |
Similar Companies
Frequently Asked Questions
What is Theravance Bioph's annual revenue?
Theravance Bioph (TBPH) reported $107.5M in total revenue for fiscal year 2025. This represents a 66.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Theravance Bioph's revenue growing?
Theravance Bioph (TBPH) revenue grew by 66.9% year-over-year, from $64.4M to $107.5M in fiscal year 2025.
Is Theravance Bioph profitable?
Yes, Theravance Bioph (TBPH) reported a net income of $105.9M in fiscal year 2025, with a net profit margin of 98.5%.
What is Theravance Bioph's EBITDA?
Theravance Bioph (TBPH) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Theravance Bioph's operating margin?
Theravance Bioph (TBPH) had an operating margin of -3.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Theravance Bioph's net profit margin?
Theravance Bioph (TBPH) had a net profit margin of 98.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Theravance Bioph's return on equity (ROE)?
Theravance Bioph (TBPH) has a return on equity of 35.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Theravance Bioph's free cash flow?
Theravance Bioph (TBPH) generated $238.5M in free cash flow during fiscal year 2025. This represents a 2109.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Theravance Bioph's operating cash flow?
Theravance Bioph (TBPH) generated $238.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Theravance Bioph's total assets?
Theravance Bioph (TBPH) had $485.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Theravance Bioph's capital expenditures?
Theravance Bioph (TBPH) invested $42K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Theravance Bioph spend on research and development?
Theravance Bioph (TBPH) invested $37.4M in research and development during fiscal year 2025.
What is Theravance Bioph's current ratio?
Theravance Bioph (TBPH) had a current ratio of 10.93 as of fiscal year 2025, which is generally considered healthy.
What is Theravance Bioph's debt-to-equity ratio?
Theravance Bioph (TBPH) had a debt-to-equity ratio of 0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Theravance Bioph's return on assets (ROA)?
Theravance Bioph (TBPH) had a return on assets of 21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Theravance Bioph's Altman Z-Score?
Theravance Bioph (TBPH) has an Altman Z-Score of 1.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Theravance Bioph's Piotroski F-Score?
Theravance Bioph (TBPH) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Theravance Bioph's earnings high quality?
Theravance Bioph (TBPH) has an earnings quality ratio of 2.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Theravance Bioph cover its interest payments?
Theravance Bioph (TBPH) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Theravance Bioph?
Theravance Bioph (TBPH) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.